Valeant Appoints Interim CEO; Pearson Remains Hospitalized

Source: Wall Street Journal

Jan 07, 2016

Former Valeant chief financial officer Howard Schiller has stepped in as interim chief executive of Valeant Pharmaceuticals.

Last week, Valeant announced 56-year old CEO J. Michael Pearson's medical leave of absence, following reports that Pearson had been hospitalized and was being treated for a severe case of pneumonia.

Schiller, who spent 24 years at Goldman Sachs before joining Valeant in late 2011, will be tasked with fulfilling Pearson's goal of cutting the company's $30 billion in long-term debt, as well as meeting the revised sales and earnings-per-share targets that Mr. Pearson announced a few weeks ago.

Read the WSJ article

View the most popular news stories in 2015 from Pharmaceutical Manufacturing.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments